



INFORMATION CITED BY APPLICANTS THAT MAY BE MATERIAL TO THE
PROSECUTION OF THE SUBJECT APPLICATION

Applicants: R.J. Speirs et al. Attorney Docket No. CHIR122149
Application No.: 10/743,529
Filed: December 22, 2003
Title: METHODS AND UNIT DOSE FORMULATIONS FOR THE INHALATION
ADMINISTRATION OF AMINOGLYCOSIDE ANTIBIOTICS

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	Document No.	Kind Code	Date (mm/dd/yyyy)	Name
<u>BS</u>	A	5,508,269	A	04/16/1996	Smith et al.
<u>BS</u>	B	6,387,886	B1	05/14/2002	Montgomery et al.
<u>BS</u>	U1	6,083,922	A	07/04/2000	Montgomery

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	Document No.	Kind Code	Publication Date (mm/dd/yyyy)	Country	English Abstract Provided	Translation Provided
<u>BS</u>	F1	WO 00/35461	A1	06/22/2000	WO		
<u>BS</u>	F2	WO 98/43650	A1	10/08/1998	WO		

OTHER INFORMATION

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial	Cite No.	
<u>BS</u>	O01	"TOBI® Tobramycin Solution for Inhalation," <i>Prescribing Information</i> , CHIRON Corporation, Emeryville, Calif., April 2001, 4 pp.
<u>BS</u>	O02	Standaert, T.A., et al., "The Choice of Compressor Effects the Aerosol Parameters and the Delivery of Tobramycin From a Single Model Nebulizer," <i>J. Aerosol Medicine</i> 13(2):147-153, 2000.
<u>BS</u>	O03	"PathoGenesis Inks Deal With AeroGen," <i>Puget Sound Business Journal</i> , ©2000 American City Business Journals Inc., < http://seattle.bizjournals.com/seattle/stories/2000/02/daily15.html > [retrieved April 15, 2004].

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{LLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



- 004 Ho, S.L., and A.L. Coates, "Effect of Dead Volume on the Efficiency and the Cost to Deliver Medications in Cystic Fibrosis With Four Disposable Nebulizers," *Can. Respir. J.* 6(3):253-260, 1999.
- 005 Kendrick, A.H., et al., "Selecting and Using Nebuliser Equipment," *Thorax* 52(Suppl 2):S92-S101, 1997.
- 006 Coates, A.L., et al., "The Choice of Jet Nebulizer, Nebulizing Flow, and Addition of Albuterol Affects the Output of Tobramycin Aerosols," *Chest* 111(5):1206-1212, 1997.
- 007 Weber, A., et al., "Effect of Nebulizer Type and Antibiotic Concentration on Device Performance," *Pediatric Pulmonology* 23:249-260, 1997.
- 008 Touw, D.J., et al., "Pharmacokinetics of Aerosolized Tobramycin in Adult Patients With Cystic Fibrosis," *Antimicrobial Agents and Chemotherapy* 41:184-187, 1997.
- 009 Faurisson, F., et al., "Étude Comparative sur les Performances et l'Ergonomie de Nébuliseurs dans la Mucoviscidose," *Rev. Mal. Resp.* 13:155-162, 1996.
- 010 Nikolaizik, W.H., et al., "Bronchial Constriction After Nebulized Tobramycin Preparations and Saline in Patients With Cystic Fibrosis," *Eur. J. Pediatrics* 155:608-611, 1996.
- 011 Weber, A., et al., "Tobramycin Serum Concentrations After Aerosol and Oral Administration in Cystic Fibrosis," *Am. J. Therapeutics* 2:81-87, 1995.
- 012 Weber, A., et al., "Nebulizer Delivery of Tobramycin to the Lower Respiratory Tract," *Pediatric Pulmonology* 17:331-339, 1994.
- 013 Cooney, G.F., et al., "Absolute Bioavailability and Absorption Characteristics of Aerosolized Tobramycin in Adults With Cystic Fibrosis," *Clin. Pharmacol.* 34:255-259, 1994.
- 014 Littlewood, J.M., et al., "Aerosol Antibiotic Treatment in Cystic Fibrosis," *Archives of Disease in Childhood* 68:788-792, 1993.
- 015 Le Conte, P., et al., "Lung Distribution and Pharmacokinetics of Aerosolized Tobramycin," *Am. Rev. Respir. Dis.* 147:1279-1282, 1993.
- 016 Ramsey, B.W., et al., "Efficacy of Aerosolized Tobramycin in Patients With Cystic Fibrosis," *New England J. Med.* 328:1740-1746, 1993.
- 017 Makhoul, I. R., et al., "Antibiotic Treatment of Experimental *Pseudomonas aeruginosa* Pneumonia in Guinea Pigs: Comparison of Aerosol and Systemic Administration," *J. Infectious Diseases* 168:1296-1299, 1993.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESSSM
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



Valcke, Y.J., and R.A. Pauwels, "Pharmacokinetic Evaluation of Tobramycin in the Alveolar Lining Fluid of the Rat After Endotracheal Administration," *Am. Rev. Respir. Dis.* 144:1199-1201, 1991.

O19 Smith, A.L., et al., "Safety of Aerosol Tobramycin Administration for 3 Months to Patients With Cystic Fibrosis," *Pediatric Pulmonology* 7:265-271, 1989.

O20 MacLusky, I.B., et al., "Long-Term Effects of Inhaled Tobramycin in Patients With Cystic Fibrosis Colonized With *Pseudomonas aeruginosa*," *Pediatric Pulmonology* 7:42-48, 1989.

O21 Steinkamp, G., et al., "Long-Term Tobramycin Aerosol Therapy in Cystic Fibrosis," *Pediatric Pulmonology* 6:91-98, 1989.

O22 Durrani, F.K., et al., "Evaluation of a New, Shorter Method of Administration of Adrenergic Aerosols in the Treatment of Asthma," *Annals of Allergy* 61:147-150, 1988.

O23 Geller, D.E., et al., "Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system," *Chest* 123:28-36, 2003.

Examiner

[Signature]

Date Considered

8/5/04

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicants.

TFB:snh/tmm/ctg

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{LLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100